Corteva sells two things that farmers need every single year: seeds and crop protection products. The seeds go in the ground each planting season. The crop protection products, which include herbicides to kill weeds, insecticides to kill bugs, and fungicides to fight disease, get sprayed on growing crops. Farmers cannot skip a year. They cannot reuse last year's seeds the same way they once could, because modern seed genetics are protected by patents and licensing agreements. So Corteva's customers come back, season after season, across roughly 110 countries. The company runs this through two segments called Seed and Crop Protection, and it sells direct to farmers through its own sales agents as well as through retail stores and distributors. The diagram below traces where the money goes.
How Corteva Makes Money
flowchart TD
A["Farmer Needs
Yield, pest control"] --> B["Seed Segment
Corn, soybean
7.0B + 1.9B"]
A --> C["Crop Protection
Herbicides, insecticides
3.7B + 1.7B + 1.1B"]
B --> D["Multi-Channel Distribution
Pioneer agency, retail,
licensing, regional brands"]
C --> D
D --> E["Customer Sales
17.4B total revenue"]
E --> F["Gross Margin
47.3 percent"]
F --> G["R&D & Supply Chain
New traits, germplasm,
product innovation"]
G --> B
G --> C
E --> H["Operating Cash Flow
3.4B annually"]
H --> I["Field Data & Insights
Real-time farmer needs,
regional adaptation"]
I --> G
H --> J["Free Cash Flow
2.8B for growth"]
J --> G
Five years of financial data tell a story of a company that stumbled in the middle and then found its footing. Revenue climbed from $15.7 billion in 2021 to $17.5 billion in 2022, then slipped back as crop protection pricing came under heavy pressure, especially in Latin America. By 2025 revenue recovered to $17.4 billion. That top-line number alone does not capture the most important shift happening inside the business.
Corteva Annual Revenue (2021 to 2025)
Revenue in billions of US dollars. Source: XBRL financials.
The more telling trend is what happened to gross margin, which is the share of each dollar of revenue left over after paying for the cost of making and sourcing products. Gross margin rose from 41.1 percent in 2021 to 47.3 percent in 2025. That means Corteva kept nearly six more cents out of every dollar compared to four years ago. This happened even as revenue was bouncing around. The company cut manufacturing costs, reduced royalty payments on older trait licenses, and shifted its product mix toward newer, higher-value offerings.
47.3%
Gross margin in 2025, up from 41.1% in 2021
Free cash flow, which is the actual cash left after running the business and paying for equipment and facilities, tells a similar story. It collapsed to just $0.3 billion in 2022, when inventory built up across the agriculture industry and customers pulled back on orders. By 2025 it recovered to $2.8 billion. The balance sheet also strengthened: net debt was negative in four of the five years, meaning Corteva held more cash than it owed in debt.
$0.3B
Free Cash Flow 2022
$2.8B
Free Cash Flow 2025
The 2022 collapse reflected an industry-wide inventory correction. The 2025 recovery came from cost cuts, volume growth, and lower raw material costs.
Research and development spending rose every year, reaching $1.474 billion in 2025. That is 8 percent of net sales, consistent across recent years. This level of spending matters because the pipeline of new seeds and new crop protection chemicals is what lets Corteva stay ahead of weeds and insects that develop resistance to older products. Without new products, older ones lose their value faster than the company can replace them.
2025
milestone
Corteva Plans to Split Into Two Companies
In October 2025, Corteva announced it intends to separate its Seed business and its Crop Protection business into two independent, publicly traded companies. The split is planned as a tax-free transaction for US shareholders. The company expects to complete the separation in the second half of 2026. Each business would then set its own strategy, make its own acquisitions, and allocate capital independently. The Seed business is pointing toward gene editing and hybrid wheat. The Crop Protection business is pointing toward biological products and operational efficiency.
Now consider the risks that could disrupt this picture. Each one is specific and documented in Corteva's own filings.
What Is a Regulatory Dossier?
Before Corteva can sell a new pesticide or a genetically modified seed in any country, it must submit a thick package of safety data called a dossier to that country's government. Regulators review it and decide whether to approve the product, restrict it, or reject it. This process can take years and cost tens of millions of dollars per product. If regulators later change their minds, a product can be pulled from shelves even after it is already generating revenue.
Regulatory approval risk sits at the top of Corteva's own risk disclosures. Getting a new seed trait or pesticide approved in each country where Corteva operates is slow, expensive, and uncertain. Losing an existing approval is an even faster way to lose revenue. Separately, a December 2025 executive order directed US antitrust enforcers to investigate whether seed companies have engaged in anti-competitive behavior. This could restrict Corteva's ability to grow through acquisitions or result in fines.
Supply chain concentration is another documented threat. A significant portion of crop protection ingredients come from China, directly or through suppliers. A conflict between China and Taiwan, or a trade disruption, could cut off those inputs faster than backup suppliers could fill the gap. This is not a theoretical worry: the 10-K names it explicitly as a high-severity risk.
What Is Weed or Insect Resistance?
When farmers spray the same herbicide or insecticide on the same fields year after year, some weeds or insects survive because they carry a natural genetic quirk that lets them resist the chemical. Those survivors reproduce, and over time the whole weed or insect population in that field becomes resistant. The old product stops working. Corteva must then develop a new product to replace it, which takes years and hundreds of millions of dollars in research.
Product pipeline risk rounds out the documented threats. Most chemicals and seed traits that enter research never reach farmers. The ones that do must get there before resistance to the older products spreads too far. Corteva also carries environmental cleanup liabilities from sites it inherited or once operated, and the cost of those cleanups can exceed the reserves set aside for them.
$650M, $700M
Expected total charges from the Crop Protection restructuring program announced in 2023
The planned split into two companies adds a layer of execution risk on top of all of the above. Management attention, legal costs, and potential disruption to shared services all become real costs during a separation. The company itself named this as a forward-looking risk in its 2025 annual report.
Corteva generates about 60 percent of its sales in the first half of each calendar year, tied to the northern hemisphere planting season. Cash collection is concentrated in the fourth quarter. This seasonal pattern means the quarterly numbers swing widely and can look alarming or impressive depending on which quarter you are reading.
The Bet
Corteva's new and pipeline products, particularly in seed traits like Enlist E3 soybeans and biological crop protection, must deliver enough pricing power and volume growth to keep gross margin expanding even as the two businesses separate into independent companies. If the separation creates cost duplication, distracts management during a critical product launch window, or if resistance to key traits spreads faster than new products can reach the market, the margin improvement of the last four years could stall before it becomes the permanent foundation of either standalone company.
Open question
Corteva's financials improved meaningfully between 2022 and 2025. Margins are higher, cash flow is stronger, and the balance sheet carries more cash than debt. The planned split into two companies is meant to unlock even more focus and value from each business. But the separation is unfinished, the antitrust environment is tightening, and a large share of crop protection ingredients depend on supply chains that run through China. Can Corteva complete the split into two companies without disrupting the margin momentum it has built, and can each standalone business sustain its own research pipeline against resistance, regulation, and competition without the scale of the combined company behind it?
Compiled · 10-K · FY2025
Regulatory Approval for Products
Corteva's seed and crop protection products must pass strict government testing and approval processes before they can be sold in different countries. If the company fails to get these approvals or loses them, it could lose the ability to sell major products, which would seriously harm sales and profits.
Antitrust and Competition Enforcement
A December 2025 executive order directs the U.S. Department of Justice and Federal Trade Commission to investigate anti-competitive behavior in food supply sectors including seeds. Regulatory actions could restrict Corteva's growth opportunities, including mergers and acquisitions, and result in fines or penalties that significantly impact operations.
Supply Chain Disruption from Geopolitical Conflict
A significant portion of Corteva's crop protection ingredients come directly or indirectly from China. A military conflict between China and Taiwan, or escalation of other global conflicts, could severely disrupt supply chains, increase costs, and reduce the company's ability to serve customers even if it uses backup suppliers.
Product Pipeline Development Risk
Corteva depends on successfully developing and launching new seed and crop protection products to grow. The development process is extremely lengthy and risky, with most chemicals and genes tested never making it to market. Weed and insect resistance can develop faster than the company can respond with new products.
Environmental Remediation Liabilities
Corteva faces ongoing costs to clean up soil and groundwater contamination at current and former facilities, including sites from businesses it divested. These cleanup costs are unpredictable and could be materially higher than the company has set aside in reserves, placing significant financial strain on the business.
10-K Item 1A · Risk Factors
